How to get Mounjaro in the UK

Mounjaro is a prescription-only medicine. That is not a formality — it means the decision to supply it is a clinical one, taken by a prescriber who has assessed you, and every lawful route in the UK runs through that decision.

Which route is open to you depends on your circumstances rather than your preference, and for most people the honest answer is that the NHS route exists but is not yet available to them.

NICE recommended tirzepatide for managing overweight and obesity in technology appraisal TA1026. That recommendation is real, and it is the reason tirzepatide can be prescribed in primary care at all. What it does not mean is that it is available to everyone who meets the licence.

NHS England is implementing the appraisal in phases over a period of up to twelve years, beginning with the people of highest clinical need. The first implementation phase covers a cohort identified as around 220,000 people over roughly three years — against a licensed-eligible population many times that size. So the rollout, not the licence, is what decides whether your practice can prescribe it to you this year.

Prioritisation is driven by comorbidity rather than by BMI alone: the number of weight-related conditions someone has is the main qualifier, used alongside BMI. One detail from the guidance deserves stating because it is rarely mentioned anywhere — BMI thresholds are set 2.5 points lower for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, because cardiometabolic risk rises at a lower BMI in those groups.

Two further conditions are worth knowing before you ask. Anyone prescribed tirzepatide in primary care must also be offered wraparound support — nutritional and dietetic advice as a minimum, with access to behavioural components. And weight management services are commissioned locally by integrated care boards, so what is available genuinely differs between areas rather than only appearing to.

The practical consequence: ask your GP, because the answer depends on your comorbidities and your ICB and neither of those is something a website can tell you. If the answer is not yet, that is a commissioning position rather than a clinical judgement about you.

A private prescription is lawful, ordinary and not a workaround. It is the same medicine, dispensed by the same kind of pharmacy, under the same licence. What differs is who pays and how quickly it happens.

What should not differ is the assessment. Weight-management medicines are classed as high-risk, and current regulatory expectations are that a prescriber verifies what you have reported rather than accepting a form as submitted — by photograph, video call, or contact with your GP. A provider that skips that step has not found a clever efficiency; it has skipped the part that makes the supply lawful.

A proper assessment covers your medical history, your current medicines, your height and weight measured rather than estimated, and anything that bears on suitability: thyroid cancer history, pancreatitis, pregnancy or planning pregnancy, diabetic eye disease, and what else you take. It can end in no, in a lower starting dose, or in a slower titration than the standard schedule. All three of those are the process working.

This takes about two minutes and it is the single most useful thing you can do before paying anyone.

Every pharmacy operating in Great Britain appears on the General Pharmaceutical Council register, which is public and searchable. Every registered online pharmacy also displays the MHRA distance selling logo, and the logo is supposed to be a working link back to the regulator’s entry for that pharmacy. A logo that is only a picture, or that links to the seller’s own page, is the thing it is pretending not to be.

Four checks, in order of how much they tell you: the pharmacy is on the GPhC register; it names its superintendent pharmacist; the distance selling logo links back to the regulator; and it will not supply without an assessment. The last one is the one no illegitimate seller can fake, because their entire business model is not doing it.

Searches for Mounjaro without a prescription are common, and the honest answer is that there is no lawful version of that transaction in the UK. There is no category of seller permitted to supply a prescription-only medicine without a prescription, and no amount of disclaimer language creates one.

What those sites ship is of unverified identity, unverified strength and unverified sterility. The risk is not mainly that it is inert — it is that it is something, at an unknown dose, injected weekly, with nobody monitoring you. Counterfeit tirzepatide pens have been found in the UK supply-adjacent market, which is precisely why the register check above matters.

If the reason you are looking at those sellers is cost, say so during an assessment instead. There is usually more than one appropriate licensed option at different price points, and a prescriber can only weigh that if they know it matters.